Employee stock grants
Fennec Pharmaceuticals Grants New Employee Incentive Stock Options Under Nasdaq Rule
Anonymous
Fennec Pharmaceuticals (NASDAQ: FENC) has granted 15,000 incentive stock options to one new non-executive employee, the company announced June 22, 2026. The options carry a $9.06 exercise price and a 10-year term, issued under the company's 2026 Equity Inducement Plan Calgary Sun.
The grant comes as Fennec rides a surge in demand for PEDMARK, its drug that protects pediatric cancer patients from hearing loss caused by cisplatin chemotherapy. The company posted $15.1 million in Q1 2026 revenue — a 73% jump from the same period last year — and has since expanded PEDMARQSI commercially into the U.K. and Germany Brantford Expositor.
How the Stock Option Grant Actually Works
Nasdaq Listing Rule 5635(c)(4) lets companies skip shareholder approval when granting equity to new hires — but only if the grant is a genuine incentive that draws the person into the job. Fennec used this same rule in May 2026, when it granted options to three other new non-executive employees covering 50,000 shares total Clinton News Record.
The new employee's 15,000 options vest in thirds. One-third unlocks on the one-year anniversary of the grant date. The rest vest monthly over the next 24 months. The employee must stay at the company to keep earning shares The Crag and Canyon.
PEDMARK's Growing Market and 2039 Patent Shield
PEDMARK remains the only FDA-approved therapy to reduce cisplatin-induced hearing loss in children. Cisplatin is widely used to treat solid tumors, but it can cause permanent damage to the inner ear. Fennec secured FDA approval in September 2022 and European Commission approval — as PEDMARQSI — in June 2023 Brantford Expositor.
In March 2026, Fennec settled a patent dispute with Cipla Limited over a generic version of PEDMARK. That settlement locks in market exclusivity until 2039. CEO Jeff Hackman has called 2026 a "defining period" for the company, pointing to field force expansion and a push into the adolescent and young adult cancer market Calgary Sun.
Analysts Bullish as Revenue and Hiring Both Accelerate
Wall Street has taken notice of Fennec's momentum. All six analysts covering the stock hold "Buy" ratings. H.C. Wainwright recently raised its price target from $13.00 to $16.00, citing adoption across new accounts. The median analyst price target now sits at $16.00, with a high of $18.00 Clinton News Record.
Analysts project Fennec will turn a profit of $18.2 million for the full year 2026. Insider ownership stands at 10.9%, a sign that management has real skin in the game. The company's market cap was roughly $302 million as of early June 2026 The Crag and Canyon.
Key Risks: Single Product, Off-Label Competition Still Loom
Fennec's growth story is not without risk. The company still depends almost entirely on one drug. Its trailing-twelve-month price-to-earnings ratio stands at -40.71, meaning it was still losing money on a recent historical basis. Short-term stock volatility is also expected as shares test resistance near $9.13–$9.24 Calgary Sun.
A cheaper, off-label form of sodium thiosulfate remains in clinical use at some centers, even though the FDA has reminded providers not to substitute it for PEDMARK. New real-world evidence presented at the 2026 ASCO Annual Meeting showed PEDMARK can be given six hours after cisplatin without hurting the drug's cancer-fighting power — a finding that could ease clinical barriers and widen adoption Brantford Expositor.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
4
Reach
4
A
AnonymousAuthor
